Metronic announced FDA approval for the MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitor. (Press release)
REAL-Time Continuous Glucose Monitoring (CGM) System, and a MiniMed
Paradigm insulin pump. The REAL-Time CGM System relays glucose
readings every five minutes from a glucose sensor to the insulin pump,
which displays to 288 readings a day nearly 100 times more
information than three daily fingersticks. REAL-Time glucose
information displayed on the insulin pump allows patients to take
immediate action to improve their glucose control after taking a
confirmatory fingerstick. The REAL-Time CGM System component is
indicated for any patient 18 years of age or older, and insulin pump
therapy for all patients requiring insulin.
The MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitor is Medtronic's fourth generation insulin pump that was originally introduced in 2002. The MiniMed pumps also have the ability to download data to the CareLink Therapy Management website – you can read a review of the MiniMed 512/712 pumps here. One of the ultimate objectives of wireless sensor technology, is to make possible a true closed-loop system that would mimic biological systems.
the development of a closed-loop insulin delivery system that may one
day mimic some functions of the human pancreas. Medtronic is testing
future systems that would employ advanced scientific algorithms to
proactively recommend insulin dosages to patients. Through this
process, Medtronic anticipates developing an external, closed-loop
system designed to simplify and improve patient diabetes management.
Pictured right is the MiniMed Paradigm REAL-Time Insulin Pump and Continuous Glucose Monitor in use. Components include A) the insulin pump, B) the cannula, a soft tube that delivers insulin for up to 3 days, C) the blood glucose sensor that can be worn for up to 3 days, and D) sensor electronics and radio that communicates to the pump.